Immune thrombocytopenia following SARS‐CoV‐2 vaccination in a female: Report of one case
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30211 ↗At a glance
Fallbericht in Pediatric Blood & Cancer, 2023. Written by Zon-Min Lee and 3 co-authors. Institution: Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. Major MEDLINE topics: COVID-19, COVID-19 Vaccines, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Cited 1 times so far (Crossref); 25 references.
Abstract (original language)
To the Editor: Immune thrombocytopenia (ITP), in the absence of other causes, is identified by a platelet count less than 100 × 109/L, which is mainly induced by immune-mediated destruction of platelets, impaired production, or increased splenic sequestration.1,2 ITP has been associated with natural infectious diseases,3 influenza,4 varicella,5 and measlesmumps-rubella vaccine.6 The pathophysiology of vaccine-related thrombocytopenia is considered associated with autoimmunity since antibodies were detected on platelets in almost 80% of the cases.1 In the coronavirus disease pandemic era, the occurrence of ITP following SARS-CoV-2 vaccination has been reported. Although the detailed mechanism is unclear,7 this is attributed to the antibodies induced by vaccination against COVID-19,8 involved in the mechanism of crossreaction andmolecularmimicry.8 With the increase in the SARS-CoV-2 vaccination rate, the occurrence of vaccination-induced ITP is gaining attention.9 A 10-year-old female, without any history of systemic diseases, presented to our hospital complaining of bluish skin following SARSCoV-2 vaccination. According to her mother’s statement, she received the Moderna vaccine on May 5, 2022; subsequently, ecchymosis and petechia developed7days later. Besides ecchymosis andpetechiae, she did not haveother symptoms, including fever, sore throat, nausea, vomiting, or bloody stools. She had consulted a local clinic within 21 days, where a platelet count of 7 × 109/L was revealed. Thirty five days post vaccination, a low platelet count of 7 × 109/L was confirmed in our hospital. The femalewithmucocutaneous bleeding presentedwith petechiae over buccal mucosa and epistaxis. Based on shared decision-making with patient’s parent, recognizing each individual’s concerns, values, and expected quality of life,10 the patient received intravenous immunoglobulin (IVIG) at a dosage of 1 g/kg/day for 2 days. The results of the infectious disease workup and coagulation studies were as follows: white blood cell: 5.7 × 109/L cells, hemoglobin: 13.5 g/dl, prothrombin time (PT): 10.9 seconds, and activated partial thromboplastin time (aPTT): 27.8 seconds. A peripheral blood smear revealed giant platelets and a normal morphology in all other cells. Serology surveys for Epstein–Barr virus, cytomegalovirus and COVID-19 virus, and workup for autoimmune diseases, including C3, C4, and anti-nuclear antibody tests, were negative, as explained in previous study.11 Moreover, relative symptoms suggestive of autoimmune diseases, such as photophobia, arthralgia, and skin rash, were lacking. After IVIG treatment, the platelet count increased to 47 × 109/L. Oral prednisolone (1 mg/kg/day) was prescribed, and a subsequent follow-up was scheduled. Within 6 months following confirmation of ITP, this patient’s platelet count remained more than 100 × 109/L under prednisolone treatment, and less than 100 × 109/L while prednisolone was tapered to less than 0.1 mg/kg/day. The previously reported adult patients responded differently to steroid treatment.12 Whether post-SARS-CoV-2 vaccination ITP cases will manifest to be self-limited or persisted and lead to chronic ITP remain undetermined. ITP may be caused by autoimmune diseases, lymphoproliferative disorders, infections,13,14 and drugs.15,16 Based on the test results and examinations, we ruled out viral infections and autoimmune disorders. Moreover, she did not show signs suggestive of thrombosis or use of any drug. ITP was eventually diagnosed based on the platelet count of 7 × 109/L, and by ruling out other possible causes.17 The patient developed associated symptoms the week after SARS-CoV-2 vaccination, and responded well to IVIG and corticosteroids, similar to a previous report.2 This is a newly diagnosed ITP instead of a persistent, refractory, or chronic one. Although the cause and effect were inconclusive, the possibility of SARS-CoV-2 vaccination-induced ITP cannot be ruled out owing to the time elapsed from vaccination till the appearance of symptoms, and the appropriate response to the treatment.18 ITP, an autoimmune disease, stimulates the proliferation of autoreactive B cells,3 resulting in auto-antibodies-associated platelet clearance or the repression of platelet formation.19 Most SARS-CoV-2 vaccination-associated ITP patients require observation or only firstline treatment with corticosteroids and/or IVIG.20 Managements should be individualized and include ease of lab monitoring, current ITP status, and risk of severe COVID-19 infection.20 Vaccineinduced immune thrombotic thrombocytopenia (VITT) is another condition involving activation of the coagulation system and platelets resulting in a high risk of mortality from thrombosis or secondary hemorrhage.21,22 As the patient did not show leg pain, redness, swelling, or neurologic symptoms that commonly occur in patients with VITT,23 and both PT and aPTT were normal, VITT was less likely.16,17 The patient lacked disease history, such as congenital thrombocytopenia and inherited platelet disorders, with a previous normal platelet count of 189× 109/L (monitored 2 years 7months before vaccination), was negative for anti-nuclear antibody test for autoimmune, with normal laboratory data, and no infectious diseases detected on
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- Department of Pharmacy, Tajen University, Pingtung, Taiwan.
- Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Department of Traditional Medicine, Chang Gung University, Linkou, Taiwan.
ORCID profiles: Zon-Min Lee
Cite
APA
Lee, Z. M., Chen, Y. C., Liu, S. C., & Wang, C. C. (2023). Immune thrombocytopenia following SARS‐CoV‐2 vaccination in a female: Report of one case. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30211
Vancouver
Lee ZM, Chen YC, Liu SC, Wang CC. Immune thrombocytopenia following SARS‐CoV‐2 vaccination in a female: Report of one case. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30211
BibTeX
@article{Lee2023,
author = {Lee, Zon-Min and Chen, Yu-Chieh and Liu, Shu-Chen and Wang, Chia-Chen},
title = {Immune thrombocytopenia following SARS‐CoV‐2 vaccination in a female: Report of one case},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30211}
}
EUVIMED